- Home
- FORR vs KOD Comparison
FORR vs KOD Comparison
Compare FORR & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- KOD
- Stock Information
- Founded
- FORR 1983
- KOD 2009
- Country
- FORR United States
- KOD United States
- Employees
- FORR N/A
- KOD N/A
- Industry
- FORR Diversified Commercial Services
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FORR Consumer Discretionary
- KOD Health Care
- Exchange
- FORR Nasdaq
- KOD Nasdaq
- Market Cap
- FORR 185.3M
- KOD 198.4M
- IPO Year
- FORR 1996
- KOD 2018
- Fundamental
- Price
- FORR $9.94
- KOD $9.79
- Analyst Decision
- FORR
- KOD Hold
- Analyst Count
- FORR 0
- KOD 4
- Target Price
- FORR N/A
- KOD $11.75
- AVG Volume (30 Days)
- FORR 83.1K
- KOD 670.2K
- Earning Date
- FORR 11-04-2025
- KOD 08-13-2025
- Dividend Yield
- FORR N/A
- KOD N/A
- EPS Growth
- FORR N/A
- KOD N/A
- EPS
- FORR N/A
- KOD N/A
- Revenue
- FORR $412,103,000.00
- KOD N/A
- Revenue This Year
- FORR N/A
- KOD N/A
- Revenue Next Year
- FORR $1.51
- KOD N/A
- P/E Ratio
- FORR N/A
- KOD N/A
- Revenue Growth
- FORR N/A
- KOD N/A
- 52 Week Low
- FORR $8.50
- KOD $1.92
- 52 Week High
- FORR $19.74
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- FORR 51.98
- KOD 57.80
- Support Level
- FORR $9.40
- KOD $8.29
- Resistance Level
- FORR $9.90
- KOD $9.23
- Average True Range (ATR)
- FORR 0.35
- KOD 0.91
- MACD
- FORR 0.03
- KOD -0.13
- Stochastic Oscillator
- FORR 61.16
- KOD 53.57
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.